News Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
14.69 ^USD	+1.45%		-0.14%	-8.42%

Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT
Mar. 04	North American Morning Briefing : Stock Futures -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04	MT
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Feb. 29	CI
Innoviva: Q4 Earnings Snapshot	Feb. 29	AQ
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	Feb. 29	MT
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	Feb. 29	BU
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	Feb. 06	CI
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	Feb. 06	AQ
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	Nov. 17	MT
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 02	AQ
Innoviva: Q3 Earnings Snapshot	Nov. 01	AQ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Nov. 01	CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 01	BU
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	Nov. 01	MT
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 01	BU
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week 2023	23-10-12	AQ
Innoviva to Participate in the Cantor Global Healthcare Conference	23-09-19	BU
Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults	23-09-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Innoviva, Inc.

Equities

INVA

US45781M1018

Summary

Filters